about
Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORTTargeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical woundingTargeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boostTargeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialReduced Mortality With Partial-Breast Irradiation for Early Breast Cancer: A Meta-Analysis of Randomized TrialsSeven fractions to deliver partial breast irradiation: the toxicity is LowLong-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery.In vivo dosimetry with radiochromic films in low-voltage intraoperative radiotherapy of the breast.Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patientsImproved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation.Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trialRadiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation.Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast CancerSeri™: A surgical scaffold for breast reconstruction or for bacterial growth?Toxicity and cosmesis following partial breast irradiation consisting of 40 Gy in 10 daily fractions.In Regard to Hepel and Wazer.Rethinking neoadjuvant chemotherapy for breast cancer.An efficient method for the correction of iatrogenic symmastia: A case series.In Reply to Park et al.A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patientsErratum to “Erratum to “The SCARE guidelines: Consensus-based surgical case report guidelines” [Int. J. Surg. 34 (2016) 180–186]” [Int. J. Surg. 36 (2016) 396]Erratum to “The SCARE guidelines: Consensus-based surgical case report guidelines” [Int. J. Surg. 34 (2016) 180–186]The SCARE Statement: Consensus-based surgical case report guidelinesLocoregional Failure in Early-Stage Breast Cancer Patients Treated With Radical Mastectomy and Adjuvant Systemic Therapy: Which Patients Benefit From Postmastectomy Irradiation?Intraoperative radiotherapy for breast cancerThe use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonographyImmunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breastBreast angiosarcoma after conservative surgery, radiotherapy and prosthesis implantIncreased tissue stiffness during mammography may contribute to carcinogenesisPitfalls in the dermoscopic diagnosis of amelanotic melanoma
P50
Q24658541-77B9354B-87F1-4A1D-BFD6-E816DB7C8826Q28271265-561EEB49-FCD4-48DF-9249-62FB8A7721C9Q28272297-6F18D51E-E992-456D-BBD0-98988B335DB0Q28285969-A8D28588-0DA4-40F9-BDDA-A05CAB58DA1FQ29031481-A7CD3B4B-E43A-49B2-ADA2-B3AFDE5B7C81Q33721910-EBAAAC21-8736-4A29-9E3D-A71B7850BC9AQ34144051-1EC38C68-436D-4F40-AFDA-A265787C04FFQ34258396-64E3ACEC-4144-4B07-BB87-DC24617D5795Q34384718-EF628E74-3953-4866-A02E-FB2AB4574D00Q34996054-9C8DB8DE-424B-4CC2-9A60-3265D9952FABQ35069309-35B69FAB-EB15-42BF-88F9-61FDCBBCE9CBQ35789363-F37A7004-FF11-4EA8-A1AC-39EFC30137EAQ36089129-A7563779-09AB-4BE0-AA91-9FA4A63081D0Q36257907-7744E23E-DF73-47A6-A01B-2C378C99360EQ37266266-555F6E67-27E4-4D18-B211-E3C854D56E81Q37487689-E535D795-1922-4AD3-9947-696B60EEDBEEQ37662085-A49CF1BF-D9C8-46A2-A8A1-A8874F2A21B3Q39012462-8ABAF1BF-6FE4-4D7B-A0F1-367352BDADE1Q42517861-1F958059-87CF-4C30-B2ED-B702EBB8F14DQ44469058-C1A704F0-DF1A-4AB8-B5FA-A405E184B147Q46123164-5108F8A3-FABD-467E-A237-A0765D0ACA94Q46233046-E10F1F60-9AD0-4537-96BC-130CB049469FQ50078489-A4A1C6B7-ACCB-45C8-AA87-F184C965C174Q52716903-FD98F9E8-317C-4AC0-87AC-1280BAB2E5E5Q53139523-E621F96D-3D0B-4B9D-9314-961D6F6FAAA9Q57570360-A83BD1DB-8138-4C25-8451-6C6B73F73273Q57781771-2C2330D3-9270-4C60-B536-ECE5524CA6ECQ57781773-0E894126-C807-4F4D-A0A9-58E6E63F5BE7Q57781779-56F0C384-E7A3-44D7-A3D0-40CE076DE5F2Q60028415-121B1834-4C57-4F1D-8381-DF194A202FA8Q61626894-46FBBF76-973B-4B9C-ABD3-C3FA1D6C33DAQ70840883-1C94063B-FF17-4562-96F1-8C4327758B08Q71398689-560C9438-B408-4F4C-B6EB-9E2EC337FA77Q74683802-CC1D99C6-E112-49C8-A11D-305A575EC02EQ80350685-A6BB1063-20B4-485D-9610-D6CAA4DACF5AQ84072241-68B81FB8-D1E1-4371-B836-2A613AD51C2D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Samuele Massarut
@ast
Samuele Massarut
@en
Samuele Massarut
@es
Samuele Massarut
@nl
Samuele Massarut
@sl
type
label
Samuele Massarut
@ast
Samuele Massarut
@en
Samuele Massarut
@es
Samuele Massarut
@nl
Samuele Massarut
@sl
prefLabel
Samuele Massarut
@ast
Samuele Massarut
@en
Samuele Massarut
@es
Samuele Massarut
@nl
Samuele Massarut
@sl
P106
P1153
6507409699
P31
P496
0000-0003-4717-0544